That should keep them in the pockets of Thiel & Angermeyer .. …
Forbes reports
A longstanding non-profit organization championing psychedelic research has accepted a sizable donation from a for-profit biopharmaceutical company listed on the Nasdaq.
The Multidisciplinary Association for Psychedelic Studies, better known as MAPS, announced today that it has accepted a US$500,000 donation from atai Impact, the philanthropic arm of Berlin-based atai Life Sciences (NASDAQ: ATAI).
In separate conversations, MAPS founder and executive director Rick Doblin and atai co-founder and CEO Florian Brand provided details about the donation and spoke broadly on how it highlights the need for greater collaboration among emerging for-profit psychedelic companies and existing non-profit organizations.
More For-Profit Companies, Less Donations
Doblin, who founded MAPS in 1986 and has been pushing for psychedelic research and policy reform since long before the so-called psychedelic renaissance, says that with the rising interest in psychedelics, many people who were previously inclined to make donations to organizations like MAPS are instead investing their money in publicly traded companies.
“As we’ve pioneered in this area, particularly with the progress we’ve made with our Phase 2 trials and heading into Phase 3, we’ve seen the rise of for-profit psychedelic companies, and it’s becoming increasingly difficult to raise donations,” says Doblin.
‘Moral Obligation’ To Support
At atai, Brand recognizes that non-profit companies in the psychedelic space are often better suited than for-profit ones at addressing areas related to mental health such as education, access, and stigmatization, and acknowledges that without organizations like MAPS, the current landscape might not exist.
More mutual love ups at
